Diagnostic yield of fusion magnetic resonance-guided prostate biopsy versus cognitive-guided biopsy in biopsy-naive patients: a head-to-head randomized controlled trial.
Mohammad-Hossein IzadpanahiAmirreza ElahianFarshad GholipourMohammad-Hatef KhorramiMahtab ZarghamMehrdad Mohammadi SichaniFarshid AlizadehFarbod KhorramiPublished in: Prostate cancer and prostatic diseases (2021)
The accuracy of identifying overall and clinically significant prostate cancer by fus-MRGB in biopsy-naive patients with PSA levels between 2 and 10 ng/dL is significantly higher than cog-MRGB and if available, we recommend using fus-MRGB over cog-MRGB in these patients.
Keyphrases
- prostate cancer
- end stage renal disease
- randomized controlled trial
- magnetic resonance
- newly diagnosed
- ejection fraction
- ultrasound guided
- chronic kidney disease
- prognostic factors
- fine needle aspiration
- peritoneal dialysis
- radical prostatectomy
- hiv infected
- study protocol
- magnetic resonance imaging
- antiretroviral therapy
- optical coherence tomography